Lin Chun-Yuan, Tsai Guochuan E, Wang Hong-Song, Wu Yu-Hsin, Chiou Chin-Chih, Wu Vivian Y, Lane Hsien-Yuan
Graduate Institute of Clinical Medical Science, College of Medicine.
J Clin Psychiatry. 2014 Sep;75(9):e924-31. doi: 10.4088/JCP.13m08843.
Previous studies suggested that antidepressants augmented with second-generation antipsychotics (SGAs), including aripiprazole, olanzapine, quetiapine, and risperidone, resulted in better treatment response or higher rates of remission in patients with major depressive disorder (MDD). However, population-based study on SGA augmentation for patients with MDD remains limited. The purpose of this study was to investigate the effectiveness of SGA augmentation for treatment of MDD using the National Health Insurance Research Database in Taiwan.
The subjects were patients with MDD (ICD-9-CM code: 296.2 and 296.3) who were initially admitted to psychiatric inpatient settings for the first time between January 1, 1996, and December 31, 2007, and could be tracked until December 31, 2011. To assess the treatment effect of SGA augmentation, 993 MDD patients who received aripiprazole, olanzapine, quetiapine, or risperidone augmentation treatment for 8 weeks or more were included in this 1-year mirror-image study. Outcome measures included length of psychiatric hospitalization and number of psychiatric admissions and emergency room (ER) visits.
After patients received SGA augmentation treatment, key psychiatric service use (including length of psychiatric hospitalization [P < .0001], number of psychiatric admissions [P < .0001], and ER visits [P = .0006]) due to MDD diagnosis was significantly reduced. Subgrouping analysis for each SGA drug also showed significant reduction in number of psychiatric admissions for MDD patients who received aripiprazole (P < .0001), olanzapine (P = .003), quetiapine (P < .0001), and risperidone (P < .0001).
The study provides support that aripiprazole, olanzapine, quetiapine, and risperidone augmentation therapy could be effective in reducing psychiatric service utilization among MDD patients.
先前的研究表明,抗抑郁药与第二代抗精神病药(SGA)联合使用,包括阿立哌唑、奥氮平、喹硫平和利培酮,可使重度抑郁症(MDD)患者获得更好的治疗反应或更高的缓解率。然而,基于人群的SGA增效治疗MDD患者的研究仍然有限。本研究的目的是利用台湾地区国民健康保险研究数据库,调查SGA增效治疗MDD的有效性。
研究对象为1996年1月1日至2007年12月31日期间首次入住精神科住院病房,且可追踪至2011年12月31日的MDD患者(国际疾病分类第九版临床修订本代码:296.2和296.3)。为评估SGA增效治疗的效果,本项为期1年的镜像研究纳入了993例接受阿立哌唑、奥氮平、喹硫平或利培酮增效治疗8周或更长时间的MDD患者。观察指标包括精神科住院时间、精神科住院次数及急诊室就诊次数。
患者接受SGA增效治疗后,因MDD诊断导致的关键精神科服务使用情况(包括精神科住院时间[P <.0001]、精神科住院次数[P <.0001]和急诊室就诊次数[P =.0006])显著减少。对每种SGA药物的亚组分析还显示,接受阿立哌唑(P <.0001)、奥氮平(P =.003)、喹硫平(P <.0001)和利培酮(P <.0001)治疗的MDD患者的精神科住院次数显著减少。
本研究支持阿立哌唑、奥氮平、喹硫平和利培酮增效治疗可有效减少MDD患者的精神科服务利用。